Investig Clin Urol.  2016 Jun;57(Suppl 1):S77-S88. 10.4111/icu.2016.57.S1.S77.

Can we use methylation markers as diagnostic and prognostic indicators for bladder cancer?

• Kim YJ
• Kim WJ

• KMID: 2426519
• DOI: http://doi.org/10.4111/icu.2016.57.S1.S77

Abstract

Urothelial carcinomas of the urinary bladder have diverse biological and functional characteristics, and numerous factors are likely to be involved in recurrence, progression, and patient survival. While several molecular markers used to evaluate the development and prognosis of bladder cancer have been studied, they are of limited value; therefore, new molecular parameters useful for predicting the prognosis of bladder cancer patients (particularly patients at high risk of progression and recurrence) are required. Recent progress in the understanding of epigenetic modification and gene silencing has provided new opportunities for the detection, treatment, and prevention of cancer. Methylation is an important molecular mechanism in bladder cancer and may have utility as a prognostic and/or diagnostic marker. This review discusses the epigenetic issues involved in the detection and prediction of bladder cancer.

Keyword

Diagnosis; Methylation; Prognosis; Urinary bladder neoplasms

MeSH Terms

Biomarkers, Tumor/blood/*genetics/urine
*DNA Methylation
Epigenesis, Genetic
Humans
Prognosis
Urinary Bladder Neoplasms/*diagnosis/genetics

Reference

1. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat E, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013; 64:639–653. PMID: 23827737.

2. Kamat AM, Hegarty PK, Gee JR, Clark PE, Svatek RS, Hegarty N, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers. Eur Urol. 2013; 63:4–15. PMID: 23083902.

3. Cheng L, Davison DD, Adams J, Lopez-Beltran A, Wang L, Montironi R, et al. Biomarkers in bladder cancer: translational and clinical implications. Crit Rev Oncol Hematol. 2014; 89:73–111. PMID: 24029603.

4. Kim WJ, Kim YJ. Epigenetic biomarkers in urothelial bladder cancer. Expert Rev Mol Diagn. 2009; 9:259–269. PMID: 19379084.

5. Besaratinia A, Cockburn M, Tommasi S. Alterations of DNA methylome in human bladder cancer. Epigenetics. 2013; 8:1013–1022. PMID: 23975266.

6. Kandimalla R, van Tilborg AA, Zwarthoff EC. DNA methylation-based biomarkers in bladder cancer. Nat Rev Urol. 2013; 10:327–335. PMID: 23628807.

7. Esteller M. Epigenetics in cancer. N Engl J Med. 2008; 358:1148–1159. PMID: 18337604.

8. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer. 2003; 3:253–266. PMID: 12671664.

9. Urakami S, Shiina H, Enokida H, Kawakami T, Kawamoto K, Hirata H, et al. Combination analysis of hypermethylated Wntantagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Clin Cancer Res. 2006; 12(7 Pt 1):2109–2116. PMID: 16609023.

10. Wolff EM, Chihara Y, Pan F, Weisenberger DJ, Siegmund KD, Sugano K, et al. Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res. 2010; 70:8169–8178. PMID: 20841482.

11. Chan MW, Chan LW, Tang NL, Tong JH, Lo KW, Lee TL, et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res. 2002; 8:464–470. PMID: 11839665.

12. Dulaimi E, Uzzo RG, Greenberg RE, Al-Saleem T, Cairns P. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res. 2004; 10:1887–1893. PMID: 15041703.

13. Hoque MO, Begum S, Topaloglu O, Chatterjee A, Rosenbaum E, Van Criekinge W, et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst. 2006; 98:996–1004. PMID: 16849682.

14. Friedrich MG, Weisenberger DJ, Cheng JC, Chandrasoma S, Siegmund KD, Gonzalgo ML, et al. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res. 2004; 10:7457–7465. PMID: 15569975.

15. Sathyanarayana UG, Maruyama R, Padar A, Suzuki M, Bondaruk J, Sagalowsky A, et al. Molecular detection of noninvasive and invasive bladder tumor tissues and exfoliated cells by aberrant promoter methylation of laminin-5 encoding genes. Cancer Res. 2004; 64:1425–1430. PMID: 14973053.

16. Chan MW, Chan LW, Tang NL, Lo KW, Tong JH, Chan AW, et al. Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients. Int J Cancer. 2003; 104:611–616. PMID: 12594816.

17. Yates DR, Rehman I, Meuth M, Cross SS, Hamdy FC, Catto JW. Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls. Oncogene. 2006; 25:1984–1988. PMID: 16288222.

18. Yu J, Zhu T, Wang Z, Zhang H, Qian Z, Xu H, et al. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin Cancer Res. 2007; 13:7296–7304. PMID: 18094410.

19. Aleman A, Cebrian V, Alvarez M, Lopez V, Orenes E, Lopez-Serra L, et al. Identification of PMF1 methylation in association with bladder cancer progression. Clin Cancer Res. 2008; 14:8236–8243. PMID: 19088041.

20. Cebrian V, Alvarez M, Aleman A, Palou J, Bellmunt J, Gonzalez-Peramato P, et al. Discovery of myopodin methylation in bladder cancer. J Pathol. 2008; 216:111–119. PMID: 18636402.

21. Costa VL, Henrique R, Danielsen SA, Duarte-Pereira S, Eknaes M, Skotheim RI, et al. Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin Cancer Res. 2010; 16:5842–5851. PMID: 20975101.

22. Lin HH, Ke HL, Huang SP, Wu WJ, Chen YK, Chang LL. Increase sensitivity in detecting superficial, low grade bladder cancer by combination analysis of hypermethylation of E-cadherin, p16, p14, RASSF1A genes in urine. Urol Oncol. 2010; 28:597–602. PMID: 19181545.

23. Renard I, Joniau S, van Cleynenbreugel B, Collette C, Naome C, Vlassenbroeck I, et al. Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the non-invasive detection of primary bladder cancer in urine samples. Eur Urol. 2010; 58:96–104. PMID: 19674832.

24. Cabello MJ, Grau L, Franco N, Orenes E, Alvarez M, Blanca A, et al. Multiplexed methylation profiles of tumor suppressor genes in bladder cancer. J Mol Diagn. 2011; 13:29–40. PMID: 21227392.

25. Chen PC, Tsai MH, Yip SK, Jou YC, Ng CF, Chen Y, et al. Distinct DNA methylation epigenotypes in bladder cancer from different Chinese sub-populations and its implication in cancer detection using voided urine. BMC Med Genomics. 2011; 4:45. PMID: 21599969.

26. Chung W, Bondaruk J, Jelinek J, Lotan Y, Liang S, Czerniak B, et al. Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. Cancer Epidemiol Biomarkers Prev. 2011; 20:1483–1491. PMID: 21586619.

27. Costa VL, Henrique R, Danielsen SA, Eknaes M, Patricio P, Morais A, et al. TCF21 and PCDH17 methylation: an innovative panel of biomarkers for a simultaneous detection of urological cancers. Epigenetics. 2011; 6:1120–1130. PMID: 21847011.

28. Dudziec E, Goepel JR, Catto JW. Global epigenetic profiling in bladder cancer. Epigenomics. 2011; 3:35–45. PMID: 22126151.

29. Reinert T, Modin C, Castano FM, Lamy P, Wojdacz TK, Hansen LL, et al. Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin Cancer Res. 2011; 17:5582–5592. PMID: 21788354.

30. Serizawa RR, Ralfkiaer U, Steven K, Lam GW, Schmiedel S, Schuz J, et al. Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events. Int J Cancer. 2011; 129:78–87. PMID: 20824703.

31. Vinci S, Giannarini G, Selli C, Kuncova J, Villari D, Valent F, et al. Quantitative methylation analysis of BCL2, hTERT, and DAPK promoters in urine sediment for the detection of nonmuscle-invasive urothelial carcinoma of the bladder: a prospective, two-center validation study. Urol Oncol. 2011; 29:150–156. PMID: 19272801.

32. Berrada N, Amzazi S, Ameziane El, Benbacer L, El Mzibri M, Khyatti M, et al. Epigenetic alterations of adenomatous polyposis coli (APC), retinoic acid receptor beta (RARβ) and survivin genes in tumor tissues and voided urine of bladder cancer patients. Cell Mol Biol (Noisy-le-grand). 2012; (Suppl. 58):OL1744–OL1751. PMID: 22992440.

33. Eissa S, Zohny SF, Shehata HH, Hegazy MG, Salem AM, Esmat M. Urinary retinoic acid receptor-β2 gene promoter methylation and hyaluronidase activity as noninvasive tests for diagnosis of bladder cancer. Clin Biochem. 2012; 45:402–407. PMID: 22286019.

34. Reinert T, Borre M, Christiansen A, Hermann GG, Orntoft TF, Dyrskjot L. Diagnosis of bladder cancer recurrence based on urinary levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 hypermethylation. PLoS One. 2012; 7:e46297. PMID: 23056278.

35. Scher MB, Elbaum MB, Mogilevkin Y, Hilbert DW, Mydlo JH, Sidi AA, et al. Detecting DNA methylation of the BCL2, CDKN2A and NID2 genes in urine using a nested methylation specific polymerase chain reaction assay to predict bladder cancer. J Urol. 2012; 188:2101–2107. PMID: 23083854.

36. Zhao Y, Guo S, Sun J, Huang Z, Zhu T, Zhang H, et al. Methylcap-seq reveals novel DNA methylation markers for the diagnosis and recurrence prediction of bladder cancer in a Chinese population. PLoS One. 2012; 7:e35175. PMID: 22529986.

37. Zuiverloon TC, Beukers W, van der Keur KA, Munoz JR, Bangma CH, Lingsma HF, et al. A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine. BJU Int. 2012; 109:941–948. PMID: 21756281.

38. Chihara Y, Kanai Y, Fujimoto H, Sugano K, Kawashima K, Liang G, et al. Diagnostic markers of urothelial cancer based on DNA methylation analysis. BMC Cancer. 2013; 13:275. PMID: 23735005.

39. Yegin Z, Gunes S, Buyukalpelli R. Hypermethylation of TWIST1 and NID2 in tumor tissues and voided urine in urinary bladder cancer patients. DNA Cell Biol. 2013; 32:386–392. PMID: 23682613.

40. Abern MR, Owusu R, Inman BA. Clinical performance and utility of a DNA methylation urine test for bladder cancer. Urol Oncol. 2014; 32:51.e21–51.e26. PMID: 24360662.

41. Su SF, de Castro Abreu AL, Chihara Y, Tsai Y, Andreu-Vieyra C, Daneshmand S, et al. A panel of three markers hyper- and hypomethylated in urine sediments accurately predicts bladder cancer recurrence. Clin Cancer Res. 2014; 20:1978–1989. PMID: 24691641.

42. Fantony JJ, Abern MR, Gopalakrishna A, Owusu R, Jack Tay K, Lance RS, et al. Multi-institutional external validation of urinary TWIST1 and NID2 methylation as a diagnostic test for bladder cancer. Urol Oncol. 2015; 33:387.e1–387.e6. PMID: 26027762.

43. Hayashi M, Bernert H, Kagohara LT, Maldonado L, Brait M, Schoenberg M, et al. Epigenetic inactivation of VGF associated with urothelial cell carcinoma and its potential as a non-invasive biomarker using urine. Oncotarget. 2014; 5:3350–3361. PMID: 24830820.

44. Christoph F, Weikert S, Kempkensteffen C, Krause H, Schostak M, Miller K, et al. Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder. Int J Cancer. 2006; 119:1396–1402. PMID: 16642478.

45. Dominguez G, Carballido J, Silva J, Silva JM, Garcia JM, Menendez J, et al. p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. Clin Cancer Res. 2002; 8:980–985. PMID: 11948103.

46. Friedrich MG, Chandrasoma S, Siegmund KD, Weisenberger DJ, Cheng JC, Toma MI, et al. Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. Eur J Cancer. 2005; 41:2769–2778. PMID: 16242928.

47. Kim WJ, Kim EJ, Jeong P, Quan C, Kim J, Li QL, et al. RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors. Cancer Res. 2005; 65:9347–9354. PMID: 16230397.

48. Tada Y, Wada M, Taguchi K, Mochida Y, Kinugawa N, Tsuneyoshi M, et al. The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res. 2002; 62:4048–4053. PMID: 12124340.

49. Kim EJ, Kim YJ, Jeong P, Ha YS, Bae SC, Kim WJ. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor. J Urol. 2008; 180:1141–1145. PMID: 18639281.

50. Maruyama R, Toyooka S, Toyooka KO, Harada K, Virmani AK, Zochbauer-Muller S, et al. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res. 2001; 61:8659–8663. PMID: 11751381.

51. Catto JW, Azzouzi AR, Rehman I, Feeley KM, Cross SS, Amira N, et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol. 2005; 23:2903–2910. PMID: 15753461.

52. Marsit CJ, Karagas MR, Andrew A, Liu M, Danaee H, Schned AR, et al. Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer. Cancer Res. 2005; 65:7081–7085. PMID: 16103055.

53. Kawamoto K, Enokida H, Gotanda T, Kubo H, Nishiyama K, Kawahara M, et al. p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer. Biochem Biophys Res Commun. 2006; 339:790–796. PMID: 16316628.

54. Yates DR, Rehman I, Abbod MF, Meuth M, Cross SS, Linkens DA, et al. Promoter hypermethylation identifies progression risk in bladder cancer. Clin Cancer Res. 2007; 13:2046–2053. PMID: 17404085.

55. Aleman A, Adrien L, Lopez-Serra L, Cordon-Cardo C, Esteller M, Belbin TJ, et al. Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays. Br J Cancer. 2008; 98:466–473. PMID: 18087279.

56. Ellinger J, El Kassem N, Heukamp LC, Matthews S, Cubukluoz F, Kahl P, et al. Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer. J Urol. 2008; 179:346–352. PMID: 18006010.

57. Alvarez-Múgica M, Cebrian V, Fernandez-Gomez JM, Fresno F, Escaf S, Sanchez-Carbayo M. Myopodin methylation is associated with clinical outcome in patients with T1G3 bladder cancer. J Urol. 2010; 184:1507–1513. PMID: 20723929.

58. Agundez M, Grau L, Palou J, Algaba F, Villavicencio H, Sanchez-Carbayo M. Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guérin response in patients with T1G3 high-risk bladder tumours. Eur Urol. 2011; 60:131–140. PMID: 21514719.

59. Cebrian V, Fierro M, Orenes-Pinero E, Grau L, Moya P, Ecke T, et al. KISS1 methylation and expression as tumor stratification biomarkers and clinical outcome prognosticators for bladder cancer patients. Am J Pathol. 2011; 179:540–546. PMID: 21683672.

60. Kandimalla R, van Tilborg AA, Kompier LC, Stumpel DJ, Stam RW, Bangma CH, et al. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers. Eur Urol. 2012; 61:1245–1256. PMID: 22284968.

61. Lin YL, Liu XQ, Li WP, Sun G, Zhang CT. Promoter methylation of H-cadherin is a potential biomarker in patients with bladder transitional cell carcinoma. Int Urol Nephrol. 2012; 44:111–117. PMID: 21516472.

62. Lin HH, Ke HL, Wu WJ, Lee YH, Chang LL. Hypermethylation of E-cadherin, p16, p14, and RASSF1A genes in pathologically normal urothelium predict bladder recurrence of bladder cancer after transurethral resection. Urol Oncol. 2012; 30:177–181. PMID: 20800513.

63. Kim YJ, Yoon HY, Kim JS, Kang HW, Min BD, Kim SK, et al. HOXA9, ISL1 and ALDH1A3 methylation patterns as prognostic markers for nonmuscle invasive bladder cancer: arraybased DNA methylation and expression profiling. Int J Cancer. 2013; 133:1135–1142. PMID: 23436614.

64. Alvarez-Mugica M, Fernandez-Gomez JM, Cebrian V, Fresno F, Escaf S, Sanchez-Carbayo M. Polyamine-modulated factor-1 methylation predicts Bacillus Calmette-Guerin response in patients with high-grade non-muscle-invasive bladder carcinoma. Eur Urol. 2013; 63:364–370. PMID: 22682992.

65. García-Baquero R, Puerta P, Beltran M, Alvarez-Mujica M, Alvarez-Ossorio JL, Sanchez-Carbayo M. Methylation of tumor suppressor genes in a novel panel predicts clinical outcome in paraffin-embedded bladder tumors. Tumour Biol. 2014; 35:5777–5786. PMID: 24577895.

66. Li H, Wang J, Xiao W, Xia D, Lang B, Wang T, et al. Epigenetic inactivation of KLF4 is associated with urothelial cancer progression and early recurrence. J Urol. 2014; 191:493–501. PMID: 24018236.

67. Lin YL, Wang YL, Ma JG, Li WP. Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer. J Exp Clin Cancer Res. 2014; 33:68. PMID: 25927589.

68. Sacristan R, Gonzalez C, Fernandez-Gomez JM, Fresno F, Escaf S, Sanchez-Carbayo M. Molecular classification of nonmuscle-invasive bladder cancer (pTa low-grade, pT1 lowg-rade, and pT1 high-grade subgroups) using methylation of tumor-suppressor genes. J Mol Diagn. 2014; 16:564–572. PMID: 24998186.

69. Wang XB, Lin YL, Li ZG, Ma JH, Li J, Ma JG. Protocadherin 17 promoter methylation in tumour tissue from patients with bladder transitional cell carcinoma. J Int Med Res. 2014; 42:292–299. PMID: 24567353.

70. Beukers W, Kandimalla R, Masius RG, Vermeij M, Kranse R, van Leenders GJ, et al. Stratification based on methylation of TBX2 and TBX3 into three molecular grades predicts progression in patients with pTa-bladder cancer. Mod Pathol. 2015; 28:515–522. PMID: 25394776.

71. Kim YW, Yoon HY, Seo SP, Lee SK, Kang HW, Kim WT, et al. Clinical implications and prognostic values of prostate cancer susceptibility candidate methylation in primary nonmuscle invasive bladder cancer. Dis Markers. 2015; 2015:402963. PMID: 26074659.

72. Ellinger J, Muller SC, Dietrich D. Epigenetic biomarkers in the blood of patients with urological malignancies. Expert Rev Mol Diagn. 2015; 15:505–516. PMID: 25719388.

73. Valenzuela MT, Galisteo R, Zuluaga A, Villalobos M, Nunez MI, Oliver FJ, et al. Assessing the use of p16(INK4a) promoter gene methylation in serum for detection of bladder cancer. Eur Urol. 2002; 42:622–628. PMID: 12477660.

74. Jablonowski Z, Reszka E, Gromadzinska J, Wasowicz W, Sosnowski M. Hypermethylation of p16 and DAPK promoter gene regions in patients with non-invasive urinary bladder cancer. Arch Med Sci. 2011; 7:512–516. PMID: 22295037.

75. Hauser S, Kogej M, Fechner G, Von Pezold J, Vorreuther R, Lummen G, et al. Serum DNA hypermethylation in patients with bladder cancer: results of a prospective multicenter study. Anticancer Res. 2013; 33:779–784. PMID: 23482744.

76. Lin YL, Sun G, Liu XQ, Li WP, Ma JG. Clinical significance of CDH13 promoter methylation in serum samples from patients with bladder transitional cell carcinoma. J Int Med Res. 2011; 39:179–186. PMID: 21672320.

77. Lin YL, Li ZG, He ZK, Guan TY, Ma JG. Clinical and prognostic significance of protocadherin-10 (PCDH10) promoter methylation in bladder cancer. J Int Med Res. 2012; 40:2117–2123. PMID: 23321168.

78. Luo ZG, Li ZG, Gui SL, Chi BJ, Ma JG. Protocadherin-17 promoter methylation in serum-derived DNA is associated with poor prognosis of bladder cancer. J Int Med Res. 2014; 42:35–41. PMID: 24366498.